Eagle Pharmaceuticals (EGRX) Initiates $50M Accelerated Share Buyback as Part of New $150M Share Buyback Authorization
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 7c, Revenues Miss
November 1, 2018 6:51 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.91, $0.07 worse than the analyst estimate of $0.98. Revenue for the quarter came in at $51.3 million versus the consensus estimate of $55.23 million.
While we were disappointed in the outcome of the fulvestrant trial, we believe in the strength of the remaining products in our pipeline and... More
Eagle Pharmaceuticals (EGRX) Reports Prelim. 3Q EPS Above Consenus, Prelim. 3Q Revenues Below Consensus
October 30, 2018 7:34 AM EDTEagle Pharmaceuticals, Inc. (NASDAQ: EGRX) today provided preliminary financial results and announced that its Board of Directors has approved a new stock repurchase program providing for the repurchase of up to an aggregate of $150 million of Eagles common stock, consisting of (i) up to $50 million in repurchases pursuant to an accelerated... More
